Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib + Irinotecan vs Cetuximab + Irinotecan in mCRC
NCT01925274Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of gedatolisib in metastatic colorectal cancer (mCRC), sponsored by Pfizer. Started Nov 2013; status: terminated.
02
Drugs
gedatolisib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01925274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01925274.